• Brigham and Women's Hospital , 1956 , Boston , MA

Medical School

  • Harvard Medical School , 1955 , Boston , MA


  • Brigham and Women's Hospital , 1959 , Boston , MA


  • National Cancer Institute , 1958 , Bethesda , MD


  • American Board of Internal Medicine


Publications powered by Harvard Catalyst Profiles

  1. COVID-19, nuclear war, and global warming: lessons for our vulnerable world. Lancet. 2020 06 27; 395(10242):1967-1968. View abstract
  2. The Genetic Landscape of Diamond-Blackfan Anemia. Am J Hum Genet. 2018 12 06; 103(6):930-947. View abstract
  3. The Pathophysiology of Acquired Aplastic Anemia: Current Concepts Revisited. Hematol Oncol Clin North Am. 2018 Aug; 32(4):581-594. View abstract
  4. Training. Pediatr Blood Cancer. 2018 02; 65(2). View abstract
  5. Cholesterol: the debate should be terminated. FASEB J. 2017 07; 31(7):2722-2728. View abstract
  6. Eulogy for the clinical research center. J Clin Invest. 2016 07 01; 126(7):2388-91. View abstract
  7. Thalassemia: a look to the future. Ann N Y Acad Sci. 2016 03; 1368(1):11-5. View abstract
  8. Amino acid uptake in erythropoiesis. Sci Signal. 2015 Apr 14; 8(372):fs9. View abstract
  9. A conversation with David Nathan. J Clin Invest. 2014 Dec; 124(12):5090-1. View abstract
  10. Hereditary xerocytosis revisited. Am J Hematol. 2014 Dec; 89(12):1142-6. View abstract
  11. A tribute to Emil Frei III. J Clin Invest. 2013 Aug 1; 123(8):3188-9. View abstract
  12. Pathophysiology and Clinical Manifestations of the ß-Thalassemias. Cold Spring Harb Perspect Med. 2012 Dec 01; 2(12):a011726. View abstract
  13. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012 Jul; 122(7):2439-43. View abstract
  14. Sickle cell disease (SCD), iNKT cells, and regadenoson infusion. Trans Am Clin Climatol Assoc. 2012; 123:312-7; discussion 317-8. View abstract
  15. Fetal hemoglobin levels and morbidity in untransfused patients with ß-thalassemia intermedia. Blood. 2012 Jan 12; 119(2):364-7. View abstract
  16. Guilt by association. Blood. 2011 Oct 06; 118(14):3758-9. View abstract
  17. Reversing the hemoglobin switch. N Engl J Med. 2010 Dec 02; 363(23):2258-60. View abstract
  18. Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am. 2010 Dec; 24(6):1005-20. View abstract
  19. A life-long quest to understand and treat genetic blood disorders. Cell. 2010 Oct 01; 143(1):17-20. View abstract
  20. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010 Aug 05; 116(5):687-92. View abstract
  21. Musings on genome medicine: Hepatitis C. Genome Med. 2010 Jan 27; 2(1):4. View abstract
  22. Sickle cell disease and stroke. Blood. 2009 Dec 10; 114(25):5117-25. View abstract
  23. Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases. Genome Med. 2009 Dec 09; 1(12):114. View abstract
  24. Musings on genome medicine: Crohn's disease. Genome Med. 2009 Nov 05; 1(11):103. View abstract
  25. Musings on genome medicine: the slow but inexorable process of medical care reform in the United States. Genome Med. 2009 Oct 12; 1(10):94. View abstract
  26. Call for a slower approach to health care reform. J Clin Invest. 2009 Oct; 119(10):2847-8. View abstract
  27. Musings on genome medicine: the Obama effect redux. Genome Med. 2009 Sep 11; 1(9):86. View abstract
  28. Musings on genome medicine: cholesterol and coronary artery disease. Genome Med. 2009 Jun 08; 1(6):60. View abstract
  29. Musings on genome medicine: cancer genetics and the promise of effective treatment. Genome Med. 2009 May 06; 1(5):49. View abstract
  30. Musings on genome medicine: gene therapy. Genome Med. 2009 Apr 03; 1(4):38. View abstract
  31. Musings on genome medicine: the Obama effect. Genome Med. 2009 Mar 09; 1(3):30. View abstract
  32. Musings on genome medicine: abuse of genetic tests. Genome Med. 2009 Feb 16; 1(2):18. View abstract
  33. Musings on genome medicine: genome wide association studies. Genome Med. 2009 Jan 20; 1(1):3. View abstract
  34. Judah Folkman, MD, 1933-2008. Pharos Alpha Omega Alpha Honor Med Soc. 2009; 4-8. View abstract
  35. Targeting the cell death-survival equation. Clin Cancer Res. 2007 Dec 15; 13(24):7250-3. View abstract
  36. Stanley J. Korsmeyer. Proc Am Philos Soc. 2007 Jun; 151(2):243-6. View abstract
  37. Acceptance of the 2006 Kober medal. J Clin Invest. 2007 Apr; 117(4):1107-13. View abstract
  38. The cancer treatment revolution. Trans Am Clin Climatol Assoc. 2007; 118:317-23. View abstract
  39. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2006 Dec; 79(6):1110-8. View abstract
  40. NIH support for basic and clinical research: biomedical researcher angst in 2006. JAMA. 2006 Jun 14; 295(22):2656-8. View abstract
  41. The several Cs of translational clinical research. J Clin Invest. 2005 Apr; 115(4):795-7. View abstract
  42. New developments in iron chelators. Curr Opin Hematol. 2005 Mar; 12(2):129-34. View abstract
  43. Thalassemia: the continued challenge. Ann N Y Acad Sci. 2005; 1054:1-10. View abstract
  44. RNA and protein evidence for haplo-insufficiency in Diamond-Blackfan anaemia patients with RPS19 mutations. Br J Haematol. 2004 Oct; 127(1):105-13. View abstract
  45. Determination can win the battle. Lancet. 2004 Jul 17-23; 364(9430):301. View abstract
  46. Acceptance of the 2003 John Howland Award: a journey in clinical research. Pediatr Res. 2004 Aug; 56(2):169-76. View abstract
  47. Clinical research and the NIH--a report card. N Engl J Med. 2003 Nov 06; 349(19):1860-5. View abstract
  48. First-trimester sex hormone binding globulin and subsequent gestational diabetes mellitus. Am J Obstet Gynecol. 2003 Jul; 189(1):171-6. View abstract
  49. Deferiprone and hepatic fibrosis. Blood. 2003 Jun 15; 101(12):5089-90; author reply 5090-1. View abstract
  50. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003 May 10; 361(9369):1597-602. View abstract
  51. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet. 2003 Jan 11; 361(9352):183; author reply 183-4. View abstract
  52. Clinical research: a tale of two studies. Trans Am Clin Climatol Assoc. 2003; 114:219-30; discussion 230-2. View abstract
  53. Academic freedom in clinical research. N Engl J Med. 2002 Oct 24; 347(17):1368-71. View abstract
  54. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood. 2002 Dec 15; 100(13):4649-54. View abstract
  55. Careers in translational clinical research-historical perspectives, future challenges. JAMA. 2002 May 08; 287(18):2424-7. View abstract
  56. Educational-debt relief for clinical investigators--a vote of confidence. N Engl J Med. 2002 Jan 31; 346(5):372-4. View abstract
  57. Comprehensive cancer centres and the war on cancer. Nat Rev Cancer. 2001 Dec; 1(3):240-5. View abstract
  58. Neurovisual abnormalities preceding the retinopathy in patients with long-term type 1 diabetes mellitus. Graefes Arch Clin Exp Ophthalmol. 2001 Sep; 239(9):643-8. View abstract
  59. Evidence for linkage of familial Diamond-Blackfan anemia to chromosome 8p23.3-p22 and for non-19q non-8p disease. Blood. 2001 Apr 01; 97(7):2145-50. View abstract
  60. The National Institutes of Health and clinical research: a progress report. Nat Med. 2000 Nov; 6(11):1201-4. View abstract
  61. Congenital bone marrow failure syndromes. Br J Haematol. 2000 Oct; 111(1):30-42. View abstract
  62. One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Blood. 1999 Apr 01; 93(7):2217-24. View abstract
  63. Academia and industry: lessons from the unfortunate events in Toronto. Lancet. 1999 Mar 06; 353(9155):771-2. View abstract
  64. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med. 1998 Dec 03; 339(23):1711-2; author reply 1713-4. View abstract
  65. Clinical research: perceptions, reality, and proposed solutions. National Institutes of Health Director's Panel on Clinical Research. JAMA. 1998 Oct 28; 280(16):1427-31. View abstract
  66. Pioneers and modern ideas. Prospective on thalassemia. Pediatrics. 1998 Jul; 102(1 Pt 3):281-3; discussion 288-9. View abstract
  67. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood. 1997 Sep 01; 90(5):1867-73. View abstract
  68. The beta c component of the granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence proliferation and beta-globin mRNA expression. Mol Med. 1996 Nov; 2(6):766-73. View abstract
  69. Cooperation between core binding factor and adjacent promoter elements contributes to the tissue-specific expression of interleukin-3. J Biol Chem. 1996 Jun 14; 271(24):14020-7. View abstract
  70. Diamond-Blackfan anemia. Natural history and sequelae of treatment. Medicine (Baltimore). 1996 Mar; 75(2):77-8. View abstract
  71. Iron Deficiency Anemia Associated with an Error of Iron Metabolism in Two Siblings: A Thirty Year Follow Up. Hematology. 1996; 1(1):65-73. View abstract
  72. An orally active iron chelator. N Engl J Med. 1995 Apr 06; 332(14):953-4. View abstract
  73. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994 Sep 01; 331(9):574-8. View abstract
  74. Interleukin-3 expression by activated T cells involves an inducible, T-cell-specific factor and an octamer binding protein. Blood. 1993 Feb 15; 81(4):928-34. View abstract
  75. Academic careers: choice and activity of graduates of a pediatric residency program 1974-1986. Trans Am Clin Climatol Assoc. 1993; 104:180-95; discussion 195-7. View abstract
  76. Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate. Exp Hematol. 1992 Nov; 20(10):1156-64. View abstract
  77. A service chief model for general pediatric inpatient care and residency training. Pediatrics. 1992 Apr; 89(4 Pt 1):601-7. View abstract
  78. Careers chosen by graduates of a major pediatrics residency program, 1974-1986. Acad Med. 1992 Apr; 67(4):272-4. View abstract
  79. Restoration of phagocyte function by interferon-gamma in X-linked chronic granulomatous disease occurs at the level of a progenitor cell. Blood. 1990 Dec 15; 76(12):2443-8. View abstract
  80. Intrinsic potential for high fetal hemoglobin production in a Druz family with beta-thalassemia is due to an unlinked genetic determinant. Hum Genet. 1990 Dec; 86(2):175-80. View abstract
  81. The effect of desferrithiocin, an oral iron chelator, on T-cell function. Blood. 1990 Nov 15; 76(10):2052-9. View abstract
  82. The treatment of Cooley's anemia. Haematologica. 1990 Sep-Oct; 75 Suppl 5:57-65. View abstract
  83. Treatment of Cooley's anemia. Blood. 1990 Aug 01; 76(3):435-44. View abstract
  84. Positive and negative elements regulate human interleukin 3 expression. Proc Natl Acad Sci U S A. 1990 Jul; 87(13):5046-50. View abstract
  85. Regulation of hematopoiesis. Pediatr Res. 1990 May; 27(5):423-31. View abstract
  86. Oral iron chelators. Semin Hematol. 1990 Apr; 27(2):83-5. View abstract
  87. The Jeremiah Metzger lecture. Regulation of hematopoiesis. Trans Am Clin Climatol Assoc. 1990; 101:135-53. View abstract
  88. Pharmacologic manipulation of fetal hemoglobin in the hemoglobinopathies. Ann N Y Acad Sci. 1990; 612:179-83. View abstract
  89. The beneficence of neonatal hematopoiesis. N Engl J Med. 1989 Oct 26; 321(17):1190-1. View abstract
  90. Granulocyte-macrophage colony-stimulating factor and interleukin-3 mRNAs are produced by a small fraction of blood mononuclear cells. Blood. 1989 Oct; 74(5):1525-30. View abstract
  91. Beta-thalassemia due to two novel nucleotide substitutions in consensus acceptor splice sequences of the beta-globin gene. Blood. 1989 Mar; 73(4):914-8. View abstract
  92. Expression of human interleukin-3 (multi-CSF) is restricted to human lymphocytes and T-cell tumor lines. Blood. 1989 Mar; 73(4):945-51. View abstract
  93. Combinations of recombinant colony-stimulating factors are required for optimal hematopoietic differentiation in serum-deprived culture. Blood. 1989 Feb 15; 73(3):688-93. View abstract
  94. Saudi Arabian sickle cell anemia. A molecular approach. Ann N Y Acad Sci. 1989; 565:143-51. View abstract
  95. Regulation of the human interleukin-3 gene. Trans Assoc Am Physicians. 1989; 102:240-51. View abstract
  96. Combinations of purified recombinant colony-stimulating factors are required for optimal hematopoietic differentiation. Trans Assoc Am Physicians. 1988; 101:282-7. View abstract
  97. Decreased hematopoietic accessory cell function following bone marrow transplantation. Exp Hematol. 1987 Nov; 15(10):1013-21. View abstract
  98. Leukemia and the regulation of hematopoiesis. Leukemia. 1987 Oct; 1(10):683-96. View abstract
  99. Analysis of hemoglobin F production in Saudi Arabian families with sickle cell anemia. Blood. 1987 Sep; 70(3):716-20. View abstract
  100. Stimulation of human hematopoietic colony formation by recombinant gibbon multi-colony-stimulating factor or interleukin 3. J Clin Invest. 1987 Sep; 80(3):818-23. View abstract
  101. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) shortens the period of neutropenia after autologous bone marrow transplantation in a primate model. J Clin Invest. 1987 Aug; 80(2):573-7. View abstract
  102. Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle cell anemia. N Engl J Med. 1987 Jan 29; 316(5):244-50. View abstract
  103. Regulation of fetal hemoglobin synthesis in sickle cell anemia. Trans Am Clin Climatol Assoc. 1987; 98:21-8. View abstract
  104. Analysis of high fetal hemoglobin production in sickle cell anemia patients from the Eastern Province of Saudi Arabia. Prog Clin Biol Res. 1987; 251:415-26. View abstract
  105. Investigations of the simian ontogenic switch from fetal to adult hemoglobin at the progenitor cell level. J Clin Invest. 1986 Dec; 78(6):1497-503. View abstract
  106. High fetal hemoglobin production in sickle cell anemia in the eastern province of Saudi Arabia is genetically determined. Blood. 1986 May; 67(5):1404-10. View abstract
  107. Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin. J Clin Invest. 1986 Jan; 77(1):74-81. View abstract
  108. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood. 1985 Dec; 66(6):1247-50. View abstract
  109. Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony-stimulating activity. J Clin Invest. 1985 Sep; 76(3):1286-90. View abstract
  110. Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis. J Clin Invest. 1985 Jun; 75(6):1999-2005. View abstract
  111. Identification of three accessory cell populations in human bone marrow with erythroid burst-promoting properties. J Clin Invest. 1985 Apr; 75(4):1278-84. View abstract
  112. Determination of the hemoglobin F program in human progenitor-derived erythroid cells. J Clin Invest. 1985 Apr; 75(4):1359-68. View abstract
  113. Regulation of fetal hemoglobin synthesis by cell cycle specific drugs. Prog Clin Biol Res. 1985; 191:475-500. View abstract
  114. Current therapy and new approaches to the treatment of thalassemia major. Ann N Y Acad Sci. 1985; 445:248-55. View abstract
  115. Regulation of fetal hemoglobin synthesis in the hemoglobinopathies. Ann N Y Acad Sci. 1985; 445:177-87. View abstract
  116. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984 Aug; 74(2):652-6. View abstract
  117. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med. 1984 Apr 05; 310(14):869-73. View abstract
  118. Hydroxyurea increases fetal hemoglobin production in sickle cell anemia. Trans Assoc Am Physicians. 1984; 97:268-74. View abstract
  119. Nutrition classics: the Journal of Clinical Investigation, volume 43, 1964. Iron deficiency anemia associated with an error of iron metabolism in two siblings. Nutr Rev. 1983 Oct; 41(10):315-7. View abstract
  120. Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man. J Clin Invest. 1983 Aug; 72(2):694-706. View abstract
  121. Synthesis of hemoglobin F in adult simian erythroid progenitor-derived colonies. J Clin Invest. 1982 Oct; 70(4):752-61. View abstract
  122. Clinical removal of iron. Annu Rev Med. 1982; 33:509-19. View abstract
  123. Exercise-induced hemolysis in xerocytosis. Erythrocyte dehydration and shear sensitivity. J Clin Invest. 1981 Sep; 68(3):631-8. View abstract
  124. Heterogeneity of DNA deletion in gamma delta beta-thalassemia. J Clin Invest. 1981 Mar; 67(3):878-84. View abstract
  125. Control of the simian fetal hemoglobin switch at the progenitor cell level. J Clin Invest. 1981 Feb; 67(2):458-66. View abstract
  126. The molecular genetics of thalassemia. Adv Hum Genet. 1981; 11:233-80. View abstract
  127. Treatment of acute myelogenous leukemia in children and adults. N Engl J Med. 1980 Aug 28; 303(9):473-8. View abstract
  128. Aplastic and hypoplastic anemia. Pediatr Clin North Am. 1980 May; 27(2):217-35. View abstract
  129. F-cell regulation. Ann N Y Acad Sci. 1980; 344:219-32. View abstract
  130. Monocytes do not inhibit peripheral blood erythroid burst forming unit colony formation. J Clin Invest. 1980 Jan; 65(1):219-23. View abstract
  131. Prenatal diagnosis of hemoglobinopathies: the New England approach. Ann N Y Acad Sci. 1980; 344:151-64. View abstract
  132. New approaches to the transfusion management of thalassemia. Blood. 1980 Jan; 55(1):55-60. View abstract
  133. Prenatal diagnosis of hemoglobinopathies. Clin Perinatol. 1979 Sep; 6(2):275-91. View abstract
  134. Progress in thalassemia research. Nature. 1979 Jul 26; 280(5720):275-6. View abstract
  135. The molecular basis of alpha-thalassemias: frequent occurrence of dysfunctional alpha loci among non-Asians with Hb H disease. Cell. 1979 May; 17(1):33-42. View abstract
  136. Partial deletion of beta-globin gene DNA in certain patients with beta 0-thalassemia. Proc Natl Acad Sci U S A. 1979 May; 76(5):2400-4. View abstract
  137. Application of endonuclease mapping to the analysis and prenatal diagnosis of thalassemias caused by globin-gene deletion. N Engl J Med. 1978 Jul 27; 299(4):166-72. View abstract
  138. Antenatal diagnosis of thalassaemia major. Br Med J. 1978 Feb 11; 1(6109):350-3. View abstract
  139. Erythroid precursors in congenital hypoplastic (Diamond-Blackfan) anemia. J Clin Invest. 1978 Feb; 61(2):489-98. View abstract
  140. Treatment of iron overload in adults with continuous parenteral desferrioxamine. Am J Med. 1977 Dec; 63(6):958-66. View abstract
  141. Continuous subcutaenous administration of deferoxamine in patients with iron overload. N Engl J Med. 1977 Aug 25; 297(8):418-23. View abstract
  142. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis. Trans Assoc Am Physicians. 1977; 90:335-41. View abstract
  143. Fetal research: an investigator's view. Villanova Law Rev. 1977 Jan; 22(2):384-94. View abstract
  144. Prenatal diagnosis of hemoglobinopathies: detection of alpha-thalassemia trait and of sickle cell disease in utero. Hemoglobin. 1977; 1(4):395-400. View abstract
  145. Prenatal diagnosis of hemoglobinopathies. A review of 15 cases. N Engl J Med. 1976 Dec 23; 295(26):1437-43. View abstract
  146. The thalassemias. N Engl J Med. 1976 Sep 23; 295(13):710-4. View abstract
  147. Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med. 1976 Jun 24; 294(26):1421-3. View abstract
  148. Prenatal diagnosis of sickle-cell anemia and alpha G Philadelphia. Study of a Fetus also at risk for H b S/beta+-thalassemia. N Engl J Med. 1976 May 06; 294(19):1040-1. View abstract
  149. The acute and transient nature of idiopathic immune hemolytic anemia in childhood. J Pediatr. 1976 May; 88(5):780-3. View abstract
  150. The molecular genetics of thalassemia. Birth Defects Orig Artic Ser. 1976; 12(8):145-59. View abstract
  151. Molecular pathology of the thalassemias. Adv Intern Med. 1976; 21:97-128. View abstract
  152. Expression of the beta-thalassemia gene in the first trimester fetus. Proc Natl Acad Sci U S A. 1975 Sep; 72(9):3633-7. View abstract
  153. Antenatal diagnosis of hemoglobinopathies: social and technical considerations. Semin Hematol. 1975 Jul; 12(3):305-21. View abstract
  154. Hemoglobin Syracuse (alpha2beta2-143(H21)His leads to Pro), a new high-affinity variant detected by special electrophoretic methods. Observations on the auto-oxidation of normal and variant hemoglobins. J Clin Invest. 1975 Mar; 55(3):469-77. View abstract
  155. Progress in the methodology for antenatal diagnosis of the beta chain hemoglobinopathies. Trans Assoc Am Physicians. 1975; 88:168-76. View abstract
  156. Ethical problems in fetal research. J Gen Educ. 1975; 27(3):165-75. View abstract
  157. Thalassemia. Annu Rev Med. 1975; 26:345-51. View abstract
  158. Globin translation in thalassemic bone marrow. Ann N Y Acad Sci. 1974 Nov 29; 241(0):253-61. View abstract
  159. In utero diagnosis of: hemoglobinopathies. Hemoglobin synthesis in fetal red cells. N Engl J Med. 1974 May 09; 290(19):1067-8. View abstract
  160. Relation of beta to gamma synthesis during the first trimester: an approach to prenatal diagnosis of thalassemia. Pediatr Res. 1974 May; 8(5):553-60. View abstract
  161. Intrauterine diagnosis of thalassemia. Ann N Y Acad Sci. 1974; 232(0):145-51. View abstract
  162. Translational control of hemoglobin synthesis in thalassemic bone marrow. Ann N Y Acad Sci. 1974; 232(0):40-3. View abstract
  163. Effects of cyanate and 2,3-diphosphoglycerate on sickling. Relationship to oxygenation. J Clin Invest. 1973 Oct; 52(10):2542-7. View abstract
  164. The mortality of acquired aplastic anemia in children. Blood. 1972 Aug; 40(2):153-62. View abstract
  165. Equal synthesis of - and -globin chains in erythroid precursors in heterozygous -thalassemia. J Clin Invest. 1972 Jul; 51(7):1906-9. View abstract
  166. Energy metabolism in human erythrocytes. II. Effects of glucose depletion. J Clin Invest. 1972 Jun; 51(6):1547-54. View abstract
  167. Thalassemia. N Engl J Med. 1972 Mar 16; 286(11):586-94. View abstract
  168. Changes in fatty acid metabolism after erythrocyte peroxidation: stimulation of a membrane repair process. J Clin Invest. 1972 Feb; 51(2):338-44. View abstract
  169. Gamma-beta thalassemia: a cause of hemolytic disease of the newborn. N Engl J Med. 1972 Jan 20; 286(3):129-34. View abstract
  170. Oxidant injury of caucasian glucose-6-phosphate dehydrogenase-deficient red blood cells by phagocytosing leukocytes during infection. J Clin Invest. 1971 Dec; 50(12):2466-73. View abstract
  171. Amino acid oxidase of leukocytes in relation to H 2 O 2 -mediated bacterial killing. J Clin Invest. 1971 Sep; 50(9):1985-91. View abstract
  172. Energy metabolism in human erythrocytes. I. Effects of sodium fluoride. J Clin Invest. 1971 Aug; 50(8):1731-7. View abstract
  173. Selective reticulocyte destruction in erythrocyte pyruvate kinase deficiency. J Clin Invest. 1971 Mar; 50(3):688-99. View abstract
  174. Endogenous production of carbon monoxide in normal and erythroblastotic newborn infants. J Clin Invest. 1971 Jan; 50(1):1-8. View abstract
  175. Normal and variant isoenzymes of human blood cell hexokinase and the isoenzyme patterns in hemolytic anemia. Blood. 1970 Aug; 36(2):219-27. View abstract
  176. Correction of metabolic deficiencies in the leukocytes of patients with chronic granulomatous disease. J Clin Invest. 1970 May; 49(5):865-70. View abstract
  177. Mild thalassemia: the result of interactions of alpha and beta thalassemia genes. J Clin Invest. 1970 Apr; 49(4):635-42. View abstract
  178. Mild thalassemia--a guide to therapy. N Engl J Med. 1969 Dec 11; 281(24):1363-4. View abstract
  179. Unbalanced globin chain synthesis in alpha-thalassemia heterozygotes. Ann N Y Acad Sci. 1969 Nov 20; 165(1):288-94. View abstract
  180. Globin chain synthesis in the alpha thalassemia syndromes. J Clin Invest. 1969 Nov; 47(11):2512-22. View abstract
  181. Failure of nitro blue tetrazolium reduction in the phagocytic vacuoles of leukocytes in chronic granulomatous disease. J Clin Invest. 1969 Oct; 48(10):1895-904. View abstract
  182. Influence of hemoglobin precipitation on erythrocyte metabolism in alpha and beta thalassemia. J Clin Invest. 1969 Jan; 48(1):33-41. View abstract
  183. Stages in the incorporation of fatty acids into red blood cells. J Clin Invest. 1968 May; 47(5):1096-108. View abstract
  184. Erythrocyte production and metabolism in anephric and uremic men. Ann N Y Acad Sci. 1968 Mar 29; 149(1):539-43. View abstract
  185. Hemoglobin F and beta thalassemia. Science. 1967 Sep 01; 157(3792):1079. View abstract
  187. ERYTHROPOIESIS IN ANEPHRIC MAN. J Clin Invest. 1964 Nov; 43:2158-65. View abstract
  192. Erythroid cell maturation and hemoglobin synthesis in megaloblastic anemia. J Clin Invest. 1962 May; 41:1086-93. View abstract
  193. The synthesis of heme and globin in the maturing human erythroid cell. J Clin Invest. 1961 Jun; 40:940-6. View abstract
  194. Hypochromic anemia and hemochromatosis--response to combined testosterone, pyridoxine, and liver extract therapy. Trans Am Clin Climatol Assoc. 1961; 73:121-35. View abstract
  195. The passage of ammonia across the blood-brain-barrier and its relation to blood pH. J Clin Invest. 1958 Dec; 37(12):1724-8. View abstract